• Explore /
  • Poster
  • / Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.

Abstract Poster

Authors

Thierry Andre

Thierry Andre

Saint-Antoine Hospital, Paris, France

Thierry Andre , Dominique Berton , Filippo G. De Braud , Giuseppe Curigliano , Wei Guo , Hadi Danaee , Sharon Lu , Ellie Im , Naureen Starling

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT02715284

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 218)

Abstract #

218

Poster Bd #

K18

Abstract Disclosures

Similar Posters

First Author: Dominique Berton

First Author: Thierry Andre

First Author: Nong Xu

First Author: Andrea Necchi